Abstract

Introduction Chronic constipation is classified into two main syndromes, irritable bowel syndrome with constipation (IBS-C) and functional constipation (FC), on the assumption that they differ along multiple clinical characteristics and are plausibly of distinct pathophysiology. We tested this assumption by applying machine learning to a large prospective cohort of comprehensively phenotyped patients with constipation. Methods Demographics, validated symptom and quality of life questionnaires, clinical examination findings, stool transit, and diagnosis were collected in 768 patients with chronic constipation from a tertiary centre. We used machine learning to compare the accuracy of diagnostic models for IBS-C and FC based on single differentiating features such as abdominal pain (a ‘unisymptomatic’ model) vs. multiple features encompassing a range of symptoms, examination findings and investigations (a ‘syndromic’ model), in order to assess the grounds for the syndromic segregation of IBS-C and FC in a statistically formalized way. Results Unisymptomatic models of abdominal pain distinguished between IBS-C and FC cohorts near-perfectly (AUC 0.97) (figure 1). Syndromic models did not significantly increase diagnostic accuracy (p > 0.15). Furthermore, syndromic models from which abdominal pain was omitted performed at chance level (AUC 0.56). Statistical clustering of clinical characteristics showed no structure relatable to diagnosis, but a syndromic segregation of 16 features differentiating patients by impact of constipation on daily life. Conclusions IBS-C and FC differ only with respect to the presence of abdominal pain, arguably a self-fulfilling difference given that abdominal pain inherently distinguishes the two in current diagnostic criteria. This suggests they are not distinct syndromes, rather a single syndrome varying along one clinical dimension. An alternative syndromic segregation is identified which needs evaluation in community-based cohorts. Our results have implications for patient recruitment into clinical trials, future disease classifications and management guidelines.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.